Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

NCT01235416 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01235416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
February 28, 2010
Enrollment
57 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

histologically or cytologically documented solid tumors